A Transcriptomic Analysis of Laryngeal Dysplasia
Fausto Maffini,Daniela Lepanto,Francesco Chu,Marta Tagliabue,Davide Vacirca,Rita De Berardinis,Sara Gandini,Silvano Vignati,Alberto Ranghiero,Sergio Taormina,Alessandra Rappa,Maria Cossu Rocca,Daniela Alterio,Susanna Chiocca,Massimo Barberis,Lorenzo Preda,Fabio Pagni,Nicola Fusco,Mohssen Ansarin
DOI: https://doi.org/10.3390/ijms25179685
2024-09-07
Abstract:This article describes how the transcriptional alterations of the innate immune system divide dysplasias into aggressive forms that, despite the treatment, relapse quickly and more easily, and others where the progression is slow and more treatable. It elaborates on how the immune system can change the extracellular matrix, favoring neoplastic progression, and how infections can enhance disease progression by increasing epithelial damage due to the loss of surface immunoglobulin and amplifying the inflammatory response. We investigated whether these dysregulated genes were linked to disease progression, delay, or recovery. These transcriptional alterations were observed using the RNA-based next-generation sequencing (NGS) panel Oncomine Immune Response Research Assay (OIRRA) to measure the expression of genes associated with lymphocyte regulation, cytokine signaling, lymphocyte markers, and checkpoint pathways. During the analysis, it became apparent that certain alterations divide dysplasia into two categories: progressive or not. In the future, these biological alterations are the first step to provide new treatment modalities with different classes of drugs currently in use in a systemic or local approach, including classical chemotherapy drugs such as cisplatin and fluorouracile, older drugs like fenretinide, and new checkpoint inhibitor drugs such as nivolumab and pembrolizumab, as well as newer options like T cell therapy (CAR-T). Following these observed alterations, it is possible to differentiate which dysplasias progress or not or relapse quickly. This information could, in the future, be the basis for determining a close follow-up, minimizing surgical interventions, planning a correct and personalized treatment protocol for each patient and, after specific clinical trials, tailoring new drug treatments.